Publication:
Metabolically healthy obesity: misleading phrase or healthy phenotype?

dc.contributor.coauthorGaipov, Abduzhappar
dc.contributor.coauthorKuwabara, Masanari
dc.contributor.coauthorHornum, Mads
dc.contributor.coauthorRaalte, Daniel H. Van
dc.contributor.kuauthorTanrıöver, Cem
dc.contributor.kuauthorÇöpür, Sidar
dc.contributor.kuauthorÖzlüşen, Batu
dc.contributor.kuauthorAkcan, Rüştü Emre
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.date.accessioned2024-12-29T09:40:46Z
dc.date.issued2023
dc.description.abstractObesity is a heterogenous condition with multiple different phenotypes. Among these a particular subtype exists named as metabolically healthy obesity (MHO). MHO has multiple definitions and its prevalence varies ac-cording to study. The potential mechanisms underlying the pathophysiology of MHO include the different types of adipose tissue and their distribution, the role of hormones, inflammation, diet, the intestinal microbiota and genetic factors. In contrast to the negative metabolic profile associated with metabolically unhealthy obesity (MUO), MHO has relatively favorable metabolic characteristics. Nevertheless, MHO is still associated with many important chronic diseases including cardiovascular disease, hypertension, type 2 diabetes, chronic kidney disease as well as certain types of cancer and has the risk of progression into the unhealthy phenotype. Therefore, it should not be considered as a benign condition. The major therapeutic alternatives include dietary modifi-cations, exercise, bariatric surgery and certain medications including glucagon-like peptide-1 (GLP-1) analogs, sodium-glucose cotransporter-2 (SGLT-2) inhibitors and tirzepatide. In this review, we discuss the significance of MHO while comparing this phenotype with MUO.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.volume111
dc.identifier.doi10.1016/j.ejim.2023.02.025
dc.identifier.eissn1879-0828
dc.identifier.issn0953-6205
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85150048473
dc.identifier.urihttps://doi.org/10.1016/j.ejim.2023.02.025
dc.identifier.urihttps://hdl.handle.net/20.500.14288/23429
dc.identifier.wos1026372600001
dc.keywordsObesity
dc.keywordsCardiometabolically healthy obesity
dc.keywordsSGLT2 inhibitors
dc.keywordsGLP-1 analogs
dc.languageen
dc.publisherElsevier
dc.sourceEuropean Journal of Internal Medicine
dc.subjectMedicine
dc.subjectGeneral and internal
dc.titleMetabolically healthy obesity: misleading phrase or healthy phenotype?
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorTanrıöver, Cem
local.contributor.kuauthorÇöpür, Sidar
local.contributor.kuauthorÖzlüşen, Batu
local.contributor.kuauthorAkcan, Rüştü Emre
local.contributor.kuauthorKanbay, Mehmet

Files